{"analyses":[{"ciLowerLimit":"0.598","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.932","estimateComment":"Stratified by IWRS Geographical Region, IWRS Prior Treatment, IWRS Menopausal Status","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00957","paramType":"Hazard Ratio (HR)","paramValue":"0.747","statisticalComment":"Stratified by Interactive Web Response Systems (IWRS) Geographical Region, IWRS Prior Treatment, IWRS Menopausal Status","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"There were not enough events to compute a median or 95% confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There were not enough events to compute a median or 95% confidence interval.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2808"},{"groupId":"OG001","value":"2829"}],"units":"Participants"}],"description":"IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.","id":"OG000","title":"150 mg Abemaciclib + Endocrine Therapy"},{"description":"Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.","id":"OG001","title":"Endocrine Therapy"}],"paramType":"MEDIAN","populationDescription":"All randomized participants (including the censored participants). 2672 participants were censored in \"150 mg Abemaciclib + Endocrine Therapy,\" 2642 participants were censored in \"Endocrine Therapy.\"","reportingStatus":"POSTED","timeFrame":"Baseline to Recurrence or Death from Any Cause (Up to 32 Months)","title":"Invasive Disease Free Survival (IDFS)","type":"PRIMARY","unitOfMeasure":"Months"}